Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA Holdings Inc. (NYSE:IQV) will have its chairman and CEO, Ari Bousbib, speak at the Baird 2022 Global Healthcare Conference in New York City on September 14, 2022, at 2:35 p.m. ET. Investors can access a live audio webcast via the IQVIA Investor Relations website, with a replay available later. IQVIA is a global leader in analytics and clinical research services, enhancing healthcare through innovative insights and technology with a workforce of approximately 82,000 across over 100 countries.
IQVIA Holdings Inc. (NYSE:IQV) will feature its CFO, Ron Bruehlman, at the Morgan Stanley Annual Global Healthcare Conference on September 13, 2022, at 11:10 a.m. ET in New York City. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is recognized for its analytics and clinical research services, employing approximately 82,000 individuals across over 100 countries.
Summary not available.
GSK and IQVIA have launched Vaccine Track, a new platform to enhance data transparency regarding adult vaccinations in the US. This resource aims to address the decline in adult immunization rates, particularly among minority populations, which saw an 18% drop in overall claims for recommended vaccinations from 2019 to 2021. The platform provides quarterly updates and diverse trend analyses, supporting public health efforts to improve vaccination rates post-pandemic. The initiative emphasizes the importance of vaccination data and could significantly impact public health policy.
IQVIA reported second-quarter 2022 revenue of $3,541 million, a 3.0% increase compared to the previous year, and 7.1% at constant currency. GAAP net income rose by 46.3% to $256 million, with diluted EPS increasing 48.9% to $1.34. Adjusted EBITDA reached $800 million, up 10.8% year-over-year. The R&D Solutions backlog grew 7.1% to $25.6 billion. For full-year guidance, revenue is now expected between $14,400 million and $14,550 million, reflecting 3.8% to 4.9% growth on a reported basis.
IQVIA Holdings Inc. (NYSE:IQV) has announced the upcoming release of its second-quarter 2022 financial results, scheduled for July 21, 2022, before the market opens. A conference call and webcast will follow at 9:00 a.m. Eastern Time that same day. The earnings release and detailed financial information will be available on the IQVIA Investor Relations website. A replay of the webcast will be accessible two hours after the event concludes, further enhancing investor engagement.
Summary not available.
IQVIA announced the appointment of Dr. Christina Mack as chief scientific officer for its Real World Solutions business, effective July 7, 2022. She succeeds Dr. Nancy Dreyer, who is retiring after nearly two decades with the company. Dr. Mack has extensive experience in real-world evidence, improving patient care. Prior to this role, she was vice president of Epidemiology and Clinical Evidence. Her strong educational background includes degrees from the University of Notre Dame and the University of North Carolina at Chapel Hill.
In 2021, oncology trial starts soared by 56% since 2016, with a record 30 novel active substances launched globally. Despite this progress, oncologists face 20-29% lower caseloads than pre-COVID-19, with over 30 million cancer screenings disrupted, risking timely diagnoses for more than 58,000 patients. Global oncology spending is projected to exceed $300 billion by 2026, while treated patients have increased by an average of 4% annually. The surge in R&D signifies a promising future for cancer treatments, although challenges from the pandemic linger.
IQVIA Holdings Inc. (NYSE:IQV) will have CFO Ron Bruehlman speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022, at 11:30 a.m. ET. A live audio webcast of the presentation will be accessible on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for life sciences, operating in over 100 countries with approximately 82,000 employees. The company emphasizes patient privacy and utilizes various technologies to enhance healthcare outcomes.